Dr. Jamile Shammo, an expert on
acute myeloid leukemia (
AML) at Rush University Medical Group in Chicago, explains that the treatment of frail elderly patients with maintenance and continuous treatments requires special interventions and approaches. Even after achieving complete
remission, patients with AML may
relapse and
maintenance treatments have been shown to
benefit disease outcomes. Patients who have attained complete remission with azacitidine, at a reduced dose or treatment intensity, have been shown in clinical trials to have good outcomes.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.